FULVESTRANT Zentiva 250 mg/5ml 2 ser pré 5 ml

7680682810017 CH-68281 L02BA03 07.16.2.

Reimbursement limitations:

FASLODEX

Traitements des patientes à la post-ménopause (ménopause naturelle ou induite) avec cancer du sein localement …

FULVESTRANT Zentiva 250 mg/5ml 2 ser pré 5 ml
FULVESTRANT Zentiva 250 mg/5ml 2 ser pré 5 ml
1 / 2
google

Details

Product number
6828101
CPT
-
Packaging group
2
Unit
Fertigspritze(n)
Composition
fulvestrantum 250 mg, alcohol benzylicus 500 mg, benzylis benzoas 750 mg, ethanolum 96 per centum 500 mg, ricini oleum raffinatum q.s. ad solutionem pro 5 ml, corresp. ethanolum 12.17 % V/V.

Articles (1)

Fulvestrant Zentiva 250 mg/5 ml, Injektionslösung in einer Fertigspritze
Injektionslösung
2
View

Official Swissmedic V2 data

Additional information from the official database

Official medical documents

Professional SmPC
Allemand
21/11/2023
Professional SmPC
Français
21/11/2023
Professional SmPC
Italien
21/11/2023

Detailed composition

Substance Quantity Type Category
(N/A)
250.0 MG Substance Wirkstoff (Principe actif)
(N/A)
500.0 MG Substance HBESI
(N/A)
750.0 MG Substance HBESI
(N/A)
500.0 MG Substance HBESI
(N/A)
- Substance HNIDK

Reimbursement information

Public price
CHF 329.05
Specialties list
Yes
Generic
Yes

Reimbursement limitation

SL addition date: 01/08/2021

Authorization holder

Helvepharm AG

8500 Frauenfeld

Authorization information

Swissmedic authorization number
68281
Drug name
Fulvestrant Zentiva, Injektionslösung in einer Fertigspritze
Galenic form
INLFS
ATC Code
L02BA03
Authorization status
Z
Dispensation category
B
First authorization
24/05/2021
Authorization expiration date
23/05/2026
IT number
07.16.2.
Domain
Human medicine
Field of application
Cytostatikum

Packaging details

Description (FR)
FULVESTRANT Zentiva 250 mg/5ml 2 ser pré 5 ml
Description (DE)
FULVESTRANT Zentiva 250 mg/5ml 2 Fertspr 5 ml
Market launch
24/05/2021
Narcotic (BTM)
No

Original drug

Faslodex, Injektionslösung
CHF 379.80
View original